Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global chronic plaque psoriasis therapeutics market was valued at USD 9.8 billion in 2024. The market is projected to grow from USD 10.6 billion in 2025 to USD 16.4 billion by 2032, exhibiting a CAGR of 6.7% during the forecast period.
Chronic plaque psoriasis is the most prevalent form of psoriasis, affecting approximately 80-90% of psoriasis patients globally. This chronic autoimmune condition is characterized by raised, inflamed, scaly patches of skin resulting from abnormal keratinocyte proliferation and immune system dysfunction. Current treatment modalities include topical corticosteroids, systemic immunosuppressants, phototherapy, and biologic therapies targeting inflammatory pathways.
The market growth is primarily driven by the increasing global prevalence of psoriasis, which affects about 2-3% of the worldwide population, with approximately 125 million patients currently living with the condition. Emerging biologic therapies such as IL-17 and IL-23 inhibitors are revolutionizing treatment paradigms due to their targeted mechanism of action and improved efficacy. Furthermore, the growing patient awareness and expanding treatment accessibility in developing economies are creating new growth opportunities. Key players like AbbVie, Novartis, and Johnson & Johnson continue to dominate the market with innovative treatments such as Skyrizi and Tremfya. However, high treatment costs and limited reimbursement policies in certain regions remain significant market constraints.
Increasing Prevalence of Chronic Plaque Psoriasis
The global chronic plaque psoriasis therapeutics market is experiencing significant growth, primarily driven by the increasing prevalence of the condition. Recent studies estimate that psoriasis affects approximately 2-3% of the global population, with chronic plaque psoriasis accounting for nearly 80-90% of all cases. The rising incidence has led to a greater demand for effective treatment options.
Biologic Therapies Revolutionizing Treatment
Advancements in biologic therapies have transformed the treatment landscape for chronic plaque psoriasis. These targeted treatments, including TNF- inhibitors, IL-17 inhibitors, and IL-23 inhibitors, have demonstrated superior efficacy compared to traditional systemic therapies, with clinical trials reporting 75-90% of patients achieving Psoriasis Area Severity Index (PASI) 75 improvement.
The global psoriasis drugs market is projected to reach $23 billion by 2027, growing at a CAGR of 8-9%, with biologics accounting for over 70% of revenue.
Increasing healthcare expenditure and improved reimbursement policies in developed nations are further driving market growth, enabling greater patient access to advanced treatment options.
MARKET CHALLENGES
High Cost of Biologic Therapies
A significant challenge facing the market is the high cost of biologic therapies, with annual treatment costs ranging from $20,000 to $60,000 per patient. This creates barriers to access, particularly in developing regions and for patients without adequate insurance coverage.
Other Challenges
Treatment Side Effects and Safety Concerns
Despite their efficacy, biologic therapies can cause serious side effects including increased risk of infections, reactivation of latent tuberculosis, and potential links to certain malignancies, requiring careful patient monitoring.
Patent Expirations and Biosimilar Competition
The market faces restraint from patent expirations of key biologic drugs, with several blockbuster psoriasis medications losing exclusivity in recent years. This has led to the entry of biosimilars, which are typically priced 20-40% lower than originator biologics, putting pressure on market revenues.
Emerging Novel Therapies
The pipeline for chronic plaque psoriasis treatments remains robust, with promising new oral small molecule drugs (such as JAK inhibitors) and targeted biologics in development. These novel therapies offer potential improvements in efficacy, safety, and convenience of administration compared to current options.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Biologics dominate the treatment landscape due to their targeted action on immune system pathways with fewer systemic side effects compared to traditional therapies. The high specificity of biologics makes them particularly effective for moderate-to-severe cases. |
| By Application |
|
Specialty Clinics are emerging as preferred treatment centers due to their specialized dermatology services and personalized treatment approaches. The shift towards outpatient care and biologics administration has increased their importance in the therapeutic delivery chain. |
| By End User |
|
Adults represent the largest patient population due to the disease's typical onset between 15-35 years. Treatment protocols vary significantly across age groups, with pediatric cases requiring cautious therapeutic approaches due to developmental considerations. |
| By Treatment Approach |
|
Combination Therapies are gaining prominence as they address multiple disease pathways simultaneously. The strategic use of biologics with topical agents shows enhanced efficacy with better safety profiles compared to monotherapy approaches. |
| By Disease Severity |
|
Moderate-to-Severe cases drive therapeutic innovation as these patients typically require systemic treatments. The unmet medical needs in this segment are fueling research into novel mechanisms of action and next-generation biologics with improved dosing regimens. |
Innovative Therapies Drive Growth in Biosimilar Competition
The chronic plaque psoriasis therapeutics market is dominated by a few pharmaceutical giants, with AbbVie leading through its blockbuster drug Humira. Novartis and Pfizer follow closely with their innovative biologic therapies. Market structure shows increasing biosimilar competition as key patents expire, prompting major players to invest in next-gen treatments.
Emerging biotechnology firms are carving out niche segments through targeted therapies and novel delivery mechanisms. Smaller players focus on personalized medicine approaches and combination therapies, creating specialized treatment options for refractory cases. The market also sees growing participation from Asian manufacturers offering cost-effective alternatives.
List of Key Chronic Plaque Psoriasis Therapeutics Companies ProfiledAbbVie Inc.
Merck & Co.
Astellas Pharma Inc.
Johnson & Johnson
Eli Lilly and Company
Amgen Inc.
UCB S.A.
Biogen Inc.
Sun Pharmaceutical Industries Ltd.
LEO Pharma A/S
The global Chronic Plaque Psoriasis Therapeutics market was valued at $X million in 2024 and is projected to reach $Y million by 2031, growing at a CAGR of Z%. Biologic drugs now account for over 60% of new psoriasis treatment prescriptions, with anti-TNF and IL-inhibitors leading adoption. High efficacy rates (75-90% skin clearance) and reduced systemic side effects drive this shift from traditional systemic therapies.
Other TrendsPersonalized Treatment Approaches
Genetic biomarker testing is enabling more targeted therapies, with JAK inhibitors showing 68% efficacy in patients with specific genetic markers. The market is segmenting into precision medicine solutions, with companion diagnostics expected to grow at 12% CAGR through 2030.
Emerging Market ExpansionAsia-Pacific psoriasis markets are growing at 8.2% CAGR due to increasing diagnosis rates and healthcare access. Local manufacturers in India and China are developing biosimilars at 30-40% lower costs than originator biologics, driving treatment affordability. North America maintains 42% market share but faces pricing pressure from payor reforms.
Pipeline Innovation
Phase III trials show promising results for novel IL-23 inhibitors with 12-month remission rates exceeding conventional therapies. Oral small molecule drugs in development could capture 18% of the market by 2026 if approved, offering convenient alternatives to injectables.
Regulatory and Access ChallengesStrict biosimilar approval pathways in the EU and US are limiting cost-saving alternatives, while emerging markets adopt faster approval frameworks. 65% of patients in developing countries lack access to advanced therapies due to reimbursement barriers, creating a $3.8B untapped market opportunity.
Regional Analysis: Chronic Plaque Psoriasis Therapeutics MarketEurope
Europe represents the second-largest market with universal healthcare systems ensuring treatment access. Western European countries lead in biologic adoption, while Eastern Europe shows growing demand. The region has stringent pricing regulations affecting market entry strategies. Germany and UK are key markets with established psoriasis treatment guidelines. Biosimilar competition is more pronounced here than in North America, improving affordability. Patient advocacy groups play a significant role in treatment access and policy development.
Asia-Pacific
The Asia-Pacific market is the fastest growing due to increasing disease awareness and healthcare investments. Japan and Australia have advanced treatment landscapes with government-approved biologics. Emerging economies like China and India are witnessing market expansion through local manufacturer participation. Cultural perceptions of psoriasis and out-of-pocket costs remain adoption barriers in some countries. Traditional medicine still competes with modern therapeutics in certain sub-regions.
South America
Brazil dominates the South American market with government-sponsored treatment programs. Access to biologics varies significantly between public and private healthcare sectors. Argentina shows steady growth in specialty dermatology services. Economic instability affects treatment affordability and healthcare budgets across the region. Local production of biosimilars is beginning to impact market dynamics.
Middle East & Africa
The Gulf Cooperation Council countries show the highest adoption rates of advanced therapies. South Africa has the most developed treatment infrastructure in sub-Saharan Africa. Many countries face challenges with treatment affordability and specialist shortages. Some nations rely heavily on international aid programs for psoriasis medications. Religious and cultural beliefs influence treatment-seeking behaviors in certain areas.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global chronic plaque psoriasis therapeutics market was valued at USD 9.8 billion in 2024 and is expected to reach USD 16.4 billion by 2032.
-> The market is projected to grow at a CAGR of 6.7% during the forecast period (2025-2032).
-> Key players include AbbVie, Novartis, Pfizer, Merck, and Johnson & Johnson, among others.
-> Key growth drivers include increasing global prevalence of psoriasis, emergence of biologic therapies, and growing patient awareness.
-> Main treatments include topical corticosteroids, systemic immunosuppressants, phototherapy, and biologic therapies.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates